In the current pre-specified analysis of the MONALEESA-2 trial, ribociclib plus letrozole demonstrated clinical efficacy and manageable tolerability in elderly patients with HR+, HER2− advanced breast cancer. This evidence concerns the gene HR and breast carcinoma.